Maxine Gowen is a director of Aceragen Inc.
Person profile
Roles
Employees
SEC CIK
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Aceragen, Inc.
11 Aug 23
144
Aceragen, Inc.
10 Aug 23
4
Merus N.V.
12 Jun 23
4
Aclaris Therapeutics, Inc.
5 Jun 23
4
Passage BIO, Inc.
26 May 23
4
IDERA PHARMACEUTICALS, INC.
27 Jun 22
4
Aclaris Therapeutics, Inc.
6 Jun 22
4
Merus N.V.
2 Jun 22
4
Passage BIO, Inc.
1 Jun 22
4
Passage BIO, Inc.
31 May 22
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Aug 23 | ACGN Aceragen | Common Stock | Sell | Dispose S | Yes | No | 0.51 | 51 | 26.01 | 0 |
8 Jun 23 | MRUS Merus | Share option Common Shares | Grant | Acquire A | No | No | 23.29 | 14,414 | 335.70 k | 14,414 |
2 Jun 23 | ACRS Aclaris Therapeutics | Common Stock | Option exercise | Acquire M | No | No | 0 | 4,507 | 0.00 | 12,301 |
2 Jun 23 | ACRS Aclaris Therapeutics | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 4,507 | 0.00 | 0 |
1 Jun 23 | ACRS Aclaris Therapeutics | RSU Common Stock | Grant | Acquire A | No | No | 0 | 4,660 | 0.00 | 4,660 |
1 Jun 23 | ACRS Aclaris Therapeutics | Stock Option Common Stock | Grant | Acquire A | No | No | 8.7 | 15,750 | 137.03 k | 15,750 |
25 May 23 | PASG Passage Bio | Director Stock Option Common Stock | Grant | Acquire A | No | No | 1 | 24,000 | 24.00 k | 24,000 |